• LAST PRICE
    45.7500
  • TODAY'S CHANGE (%)
    Trending Up0.5800 (1.2840%)
  • Bid / Lots
    45.6700/ 2
  • Ask / Lots
    45.7700/ 2
  • Open / Previous Close
    44.7800 / 45.1700
  • Day Range
    Low 43.9750
    High 45.9100
  • 52 Week Range
    Low 15.4401
    High 48.6100
  • Volume
    608,362
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 45.17
TimeVolumeRVMD
09:32 ET906045.0999
09:34 ET90044.64
09:36 ET30044.9606
09:38 ET30044.86
09:39 ET50044.57
09:41 ET101544.58
09:45 ET807744.3
09:48 ET211544.2763
09:50 ET146644.265
09:52 ET577444.3
09:54 ET1001444.09
09:56 ET418544.06
09:57 ET344144.055
09:59 ET123944.09
10:01 ET83444.13
10:03 ET170644.135
10:06 ET371144.2
10:08 ET200044.045
10:10 ET581244.28
10:12 ET30044.26
10:14 ET110044.23
10:15 ET30044.175
10:17 ET20044.16
10:19 ET243844.325
10:21 ET20044.395
10:24 ET20044.4
10:26 ET154544.23
10:28 ET30044.5
10:30 ET118244.58
10:32 ET20350444.86
10:33 ET453945.375
10:35 ET112245.59
10:37 ET170045.415
10:39 ET210645.34
10:42 ET30045.44
10:50 ET20045.44
10:51 ET60045.59
10:53 ET190045.48
10:55 ET66445.47
10:57 ET280045.4602
11:00 ET286645.365
11:02 ET20045.4
11:04 ET85445.415
11:06 ET40045.58
11:08 ET482545.77
11:09 ET210145.635
11:11 ET2112245.625
11:13 ET290045.575
11:15 ET1102545.6
11:18 ET20045.67
11:20 ET2504545.825
11:22 ET23445.85
11:24 ET90045.6
11:26 ET175145.78
11:27 ET452645.8
11:29 ET102545.73
11:33 ET474845.75
11:36 ET518945.795
11:38 ET445245.79
11:42 ET50045.775
11:44 ET80045.78
11:45 ET81645.795
11:47 ET74645.75
11:49 ET21745.79
11:51 ET70045.825
11:54 ET160045.82
11:58 ET70045.815
12:00 ET40045.85
12:02 ET339445.86
12:03 ET78245.84
12:05 ET178545.745
12:07 ET80045.81
12:09 ET42145.77
12:12 ET80845.715
12:14 ET20045.71
12:16 ET60045.78
12:18 ET20045.71
12:20 ET132545.665
12:21 ET10045.665
12:25 ET90045.76
12:27 ET10045.81
12:30 ET112545.86
12:32 ET70045.73
12:34 ET20045.73
12:36 ET110045.73
12:38 ET40045.69
12:39 ET10045.695
12:43 ET20045.73
12:45 ET146945.72
12:48 ET40045.71
12:50 ET10045.65
12:52 ET190045.64
12:54 ET10045.645
12:57 ET264545.64
12:59 ET33945.67
01:01 ET550045.56
01:03 ET231045.5
01:06 ET10045.54
01:08 ET10045.52
01:10 ET482545.51
01:12 ET500045.52
01:14 ET187145.42
01:15 ET40045.38
01:17 ET50045.35
01:19 ET11045.395
01:21 ET30045.48
01:24 ET10045.485
01:28 ET72545.49
01:30 ET103545.57
01:32 ET110045.485
01:33 ET30045.58
01:35 ET192545.47
01:37 ET16645.44
01:39 ET48445.58
01:46 ET347645.7
01:48 ET142245.75
01:50 ET20045.81
01:51 ET30045.835
01:53 ET10045.78
01:57 ET215045.77
02:00 ET12545.77
02:02 ET42345.765
02:04 ET10045.765
02:06 ET260545.75
02:08 ET120045.67
02:09 ET60045.68
02:11 ET30045.755
02:13 ET70045.75
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRVMD
Revolution Medicines Inc
7.5B
-12.6x
---
United StatesVKTX
Viking Therapeutics Inc
6.9B
-68.4x
---
United StatesNUVL
Nuvalent Inc
6.7B
-37.0x
---
United StatesCYTK
Cytokinetics Inc
6.2B
-9.9x
---
United StatesRNA
Avidity Biosciences Inc
5.7B
-16.0x
---
United StatesKRYS
Krystal Biotech Inc
5.2B
48.5x
---
As of 2024-10-02

Company Information

Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Company’s RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.

Contact Information

Headquarters
700 Saginaw DrREDWOOD CITY, CA, United States 94063-4752
Phone
415-766-3638
Fax
302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith
Chief Financial Officer
Jack Anders
President - Research and Development
Steve Kelsey
Chief Operating Officer
Margaret Horn
Executive Vice President - Development
Xiaolin Wang

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$7.5B
Revenue (TTM)
$742.0K
Shares Outstanding
167.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.43
EPS
$-3.65
Book Value
$11.09
P/E Ratio
-12.6x
Price/Sales (TTM)
10,168.7
Price/Cash Flow (TTM)
---
Operating Margin
-81,338.68%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.